Dubbed Engility CTMS, the new clinical trial management system (CTMS) is designed to boost the level of governance and control required by organisations to maintain effective monitoring of their trials.
The platform is said to feature automation, intuitive interface and flexible cloud architecture. It can be leveraged by any biopharmaceutical or medical device company.
Pharmaseal further noted that Engility CTMS can deliver new product updates within a managed validation framework.
The system can track study design and progress such as enrolment, milestones and required documents. It can also be used to maintain relevant institutions, investigators, IRB/IEC’s and study teams.
In addition, companies will be able to plan, track and support global site and investigator payments, as well as schedule and trigger payment requests.
Pharmaseal CEO and founder Daljit Cheema said: “We are extremely proud to finally launch our new company and release our innovative CTMS product. Our collective passion for continuous innovation led to developing the Engility platform and our first product, Engility CTMS.
“With Engility, we can enable more companies to improve their governance and oversight processes. Pharmaseal has proven that by applying advanced engineering and automation, technology can streamline and consolidate complex trial management activities.”
The platform can be easily integrated into eClinical application portfolio, including EDC and eTMF, through REST API. Pharmaseal added that the system improves clinical trial transparency.